InsidersTradesSigma
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Insider track record
CFODisclosed buys
3
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the complete record of transactions filed by Ferguson Matthew, Chief Financial Officer. Director active across 2 companies, notably Aziyo Biologics, INC.. Aggregated, 14 filings have been published. Breakdown: 3 buys · 0 sell. Total volume traded: €47k. History available since 10 May 2021. The latest transaction was filed on 31 July 2024 (Levée d'options). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations14 total
1,287 sharesClass A Common StockSEC:0001415889-25-007697:0
12,500 sharesClass A Common StockSEC:0001415889-24-028994:0
29,500 sharesClass A Common StockSEC:0001415889-24-023299:0
50,000 sharesClass A Common StockSEC:0001415889-24-021194:0
105,080 shares@ US$1.4275100.0% of flowClass A Common StockSEC:0001415889-24-020441:0
25,000 sharesClass A Common StockSEC:0001415889-24-016513:0
1,288 shares0Class A Common StockSEC:0001415889-24-007995:0
70,053 sharesClass A Common StockSEC:0001415889-23-013473:0
1,287 shares0Class A Common StockSEC:0001415889-23-004624:0
6,000 shares@ US$4.0349.0% of flowClass A Common StockSEC:0001415889-22-012089:0
Ideal exit: 29 Aug 2023 (T+270)
13,874 sharesClass A Common StockSEC:0001415889-22-009542:0
1,288 shares0Class A Common StockSEC:0001415889-22-002860:0
1,300 shares@ US$11.1450.0% of flowClass A Common StockSEC:0001104659-21-065258
Ideal exit: 4 Feb 2022 (T+270)
1,300 shares@ US$11.1450.0% of flowClass A Common StockSEC:0001104659-21-065258:0
Ideal exit: 4 Feb 2022 (T+270)
14 of 14 declarations
About Ferguson Matthew
Matthew Ferguson is the Chief Financial Officer of AZIYO BIOLOGICS, INC. In this role, he oversees the financial operations and strategy of the company. His experience in the biotechnology sector allows him to provide valuable insights on financial management and compliance. He is committed to supporting the company's growth initiatives.
